Hubei Guangji Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Hubei Guangji Pharmaceutical Co Ltd cash flow reinvestment rate. Hubei Guangji Pharmaceutical Co Ltd (000952) has a Cash Flow Reinvestment Rate of 0.39x as of September 2025, reinvesting CN¥8.67 Million (capex CN¥8.67 Million ) from operating cash flow of CN¥22.38 Million. See Hubei Guangji Pharmaceutical Co Ltd (000952) flexibility index to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Hubei Guangji Pharmaceutical Co Ltd (1999–2025)
Cash flow reinvestment rate of Hubei Guangji Pharmaceutical Co Ltd from 1999 to 2025. Historical reinvestment intensity for Hubei Guangji Pharmaceutical Co Ltd across 20 annual periods. Explore Hubei Guangji Pharmaceutical Co Ltd (000952) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Hubei Guangji Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (1999–2025)
Hubei Guangji Pharmaceutical Co Ltd cash flow reinvestment rate by year from 1999 to 2025. Year-by-year capital reinvestment analysis for Hubei Guangji Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Hubei Guangji Pharmaceutical Co Ltd (000952) cash conversion ratio.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.59x | CN¥35.64 Million | CN¥60.43 Million | CN¥35.64 Million | ▼ -99.9% |
| 2024 | 469.53x | CN¥307.71 Million | CN¥655.36K | CN¥154.93 Million | ▲ +7360.6% |
| 2022 | 6.29x | CN¥283.71 Million | CN¥45.08 Million | CN¥203.71 Million | ▲ +309.7% |
| 2021 | 1.54x | CN¥116.61 Million | CN¥75.91 Million | CN¥96.61 Million | ▲ +16.1% |
| 2020 | 1.32x | CN¥157.89 Million | CN¥119.38 Million | CN¥97.89 Million | ▲ +6.1% |
| 2019 | 1.25x | CN¥179.76 Million | CN¥144.20 Million | CN¥119.76 Million | ▲ +111.3% |
| 2018 | 0.59x | CN¥136.53 Million | CN¥231.44 Million | CN¥76.53 Million | ▼ -25.1% |
| 2017 | 0.79x | CN¥140.91 Million | CN¥178.83 Million | CN¥80.91 Million | ▼ -40.7% |
| 2016 | 1.33x | CN¥222.03 Million | CN¥167.07 Million | CN¥112.94 Million | ▲ +152.7% |
| 2013 | 0.53x | CN¥50.04 Million | CN¥95.16 Million | CN¥50.04 Million | ▼ -51.6% |
| 2012 | 1.09x | CN¥117.46 Million | CN¥108.02 Million | CN¥117.46 Million | ▼ -55.7% |
| 2011 | 2.45x | CN¥200.96 Million | CN¥81.88 Million | CN¥200.96 Million | ▲ +63.9% |
| 2010 | 1.50x | CN¥115.57 Million | CN¥77.18 Million | CN¥115.57 Million | ▲ +50.4% |
| 2008 | 1.00x | CN¥219.76 Million | CN¥220.70 Million | CN¥219.76 Million | ▲ +575.4% |
| 2007 | 0.15x | CN¥48.94 Million | CN¥331.98 Million | CN¥48.94 Million | ▼ -0.9% |
| 2006 | 0.15x | CN¥18.73 Million | CN¥125.95 Million | CN¥18.73 Million | ▼ -68.8% |
| 2005 | 0.48x | CN¥25.84 Million | CN¥54.14 Million | CN¥25.84 Million | ▼ -28.0% |
| 2002 | 0.66x | CN¥50.52 Million | CN¥76.20 Million | CN¥50.52 Million | ▲ +28.3% |
| 2000 | 0.52x | CN¥25.11 Million | CN¥48.57 Million | CN¥25.11 Million | ▼ -73.9% |
| 1999 | 1.98x | CN¥135.58 Million | CN¥68.57 Million | CN¥135.58 Million | — |